

# pDUO2-mcs

A plasmid containing two multiple cloning sites and the hygromycin resistance gene

Catalog code: pduo2-mcs

<https://www.invivogen.com/pduo-mcs>

For research use only

Version 19124-MM

## PRODUCT INFORMATION

### Contents

- 20 µg of pDUO2-mcs provided as lyophilized DNA
- 1 ml of Hygromycin B Gold at 100 mg/ml

### Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Hygromycin B Gold at 4°C or -20°C. The expiry date is specified on the product label.

### Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

## GENERAL PRODUCT USE

Toll-Like receptors (TLRs) play a critical role in early innate immunity to invading pathogens by sensing microorganisms. These evolutionary conserved receptors, homologues of the *Drosophila* Toll gene, recognize highly conserved structural motifs only expressed by microbial pathogens, called pathogen-associated microbial patterns (PAMPs). PAMPs include various bacterial cell wall components such as lipopolysaccharides (LPS), peptidoglycans and lipopeptides, as well as flagellin, bacterial DNA and viral double-stranded RNA. Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK. This signaling cascade leads to the activation of the transcription factor NF-κB which induces the secretion of pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response.

Ten human and twelve murine TLRs have been characterized, TLR1 to TLR10 in humans, and TLR1 to TLR9, TLR11, TLR12 and TLR13 in mice, the homolog of TLR10 being a pseudogene. In many instances, TLRs require the presence of a co-receptor to initiate the signaling cascade. One example is TLR4 which interacts with MD2 and CD14 to induce NF-κB in response to LPS stimulation.

pDUO2 is an expression vector designed to co-express two TLRs or TLR-related genes known to interact with each other.

The genes cloned into pDUO comprise the coding sequence (without introns) from the ATG to the Stop codon.

pDUO2-mcs does not contain a TLR gene and can be used in conjunction with other vectors of the pDUO2 family to serve as experimental controls

## PLASMID FEATURES

• **hFerH and hFerL composite promoters:** Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein<sup>4</sup>. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.

**MCS1** includes the following restriction sites:

*Age I, Eco RV, Bam HI, Sal I and Avr II*

- *Age I* is compatible with *Bsp EI* and *Sgr AI*

- *Eco RV* is compatible with any blunt-end restriction enzymes

- *Bam HI* is compatible with *Bgl II, Bst YI* and *Bcl I*

- *Sal I* is compatible with *Ava I* and *Xho I*

- *Avr II* is compatible with *Xba I, Spe I* and *Nhe I*

**MCS2** includes the following restriction sites:

*Sgr AI, Bgl II, Xho I and Nhe I*

- *Sgr AI* is compatible with *Bsp EI* and *Age I*

- *Bgl II* is compatible with *Bam HI, Bst YI* and *Bcl I*

- *Xho I* is compatible with *Ava I* and *Sal I*

- *Nhe I* is compatible with *Xba I, Spe I* and *Avr II*

• **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids<sup>5</sup>.

• **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer<sup>6</sup>.

• **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*<sup>7</sup>

• **pMB1 Ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression<sup>8</sup>.

## TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: [info@invivogen.com](mailto:info@invivogen.com)

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **hph gene** confers resistance to Hygromycin B both in *E. coli* and mammalian cells. In bacteria, *hph* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *hph* is transcribed from the human FerH composite promoter as a polycistronic mRNA and translated via the FMDV IRES.
- **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H<sub>2</sub>O. Store resuspended plasmid at -20°C.

### Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

### Hygromycin B usage:

This antibiotic can be used for *E. coli* at 50-100 µg/ml in liquid or solid media and at 50-500 µg/ml to select Hygromycin-resistant mammalian cells.

## References


1. Miyake K. *et al.*, 2000. Innate recognition of lipopolysaccharide by Toll-like receptor 4/MD-2 and RP105/MD-1. *J Endotoxin Res.* 6(5):389-91.
2. Miyake K. *et al.*, 1998. Mouse MD-1, a molecule that is physically associated with RP105 and positively regulates its expression. *J Immunol.* 161(3):1348-53.
3. Nagai Y. *et al.*, 2002. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. *Blood* 99(5):1699-705.
4. Eisenstein R.S. & Munro H.N., 1990. Translational regulation of ferritin synthesis by iron. *Enzyme* 44(1-4):42-58.
5. Dean D.A. *et al.*, 1999. Sequence requirements for plasmid nuclear import. *Exp. Cell. Res.* 253:713-22.
6. Boshart M. *et al.*, 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 141(2):521-30.
7. Carswell S. & Alwine J.C., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
8. Ramesh N. *et al.*, 1996. High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. *Nucleic Acids Res.* 24(14):2697-700.

---

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
 InvivoGen USA (International): +1 (858) 457-5873  
 InvivoGen Europe: +33 (0) 5-62-71-69-39  
 InvivoGen Hong Kong: +852 3622-3480  
 E-mail: [info@invivogen.com](mailto:info@invivogen.com)





1 CCTGCAGGCGTTACATAAAGTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAA  
101 CGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCC  
201 TATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTTATGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC  
301 GCTATTACCATGATGATGCGGTTTTGGCAGTACATCAATGGCGTGGATAGCGGTTTACTCACGGGATTTCCAAGTCTCCACCCATTGACGTCAATG  
401 GGAGTTTGTGTTGACTAGT CAGGGCCCAACCCCAAGCCCAATTTACAACACGCTGGCGCTACAGGCGCGTGACTTCCCTTGTCTTGGGCGGG  
BspEI (521)  
501 GGGCTGAGACTCCTATGTGCTCCGATTGGTCAAGCACGGCCTTCGGCCCCGCTCCTGCCACCGCAGATTGGCCGCTAGCCCTCCCGAGCGCCTGCC  
601 TCCGAGGCGCGGCACCATAAAAAGAAGCCGCTAGCCACGTCCCTCGCAGTTGCGGGTCCGCGGGTGTCTCAAGTTGCCGCCAGAACAACAGG  
XmnI (768)  
701 taagtgcgctgtgtggttccgcgcccctggcctctttacgggtatggccttgctgccttgaattacttccatgcccctggctgcagtagctgattc  
801 ttgatcccgagcttcgggttgaagtgggtgggagagttcgagccttgcttaaggagcccccttcgctcgtgcttgagttgagggcctggcttggcg  
901 ctggggcccgctgtaatactggtggcaccttcgctcgtctcgtcttctgctaagtctctagccatttaaaatgataaacagctgcgacg  
1001 cttttttctggcgagatagcttgaatgcccagagatctgcacactggtatctcggttttggggccgcccggcgagcgggcccgtgctccc  
1101 agcgcacatgttcggcgagggggcctgcgagcgcggccaccgagaatcggagcgggtagctcctaaactggcggcctgctcgtgctggcctgcg  
1201 gccgcgctgtatcggcggcctggcggaaggctggcccggctggcaccagttgctgtagcggaaagatggcgcttcccggcctgctcagggagc  
SmaI (1323)  
1301 tcaaatggaggacgcggcggcgggagagcgggctgagtcaccacacaaagaaaaggccttctcctcatcgtcgttcatgtgactcca  
1401 cggagtaccggcgcgctccaggcacctcgattagttgtcgagctttggagtagctcgtcttaggttgggggaggggtttatgcatggagtttcc  
1501 ccacactgagtggtggagactgaagagttagccagcttggcactgatgtaattctccttggatgttgcctcttgcctcattc  
FspI (1681) EcoRI (1691)  
SgrAI (1672) BglII (1685) BstBI (1698)  
1601 tcaagcctcagacagtggttcaagttttttcttccatttcagGTGTCGTGAAAACACCCTAAAAGCACCGCGTGGCAAGATCTGAATTTCTCG  
NheI (1709)  
XhoI (1703)  
1701 AACTCGAGGCTAGCTGGC CAGACATGATAAGATACATTGATGAGTTGGACAACCAACTAGAAATGCAGTGAATAAATGCTTTATTTGTGAAATTTG  
HpaI (1849)  
1801 TGATGCTATTGCTTTATTTGTAACCATTATAAGTGAATAAACAAGTTAACAACAATTGCATTATTTTATGTTTCAGGTTGAGGGGAGGTGTGG  
PacI (1953)  
1901 GAGGTTTTTAAAGCAAGTAAAACCTCTACAATGTGGTATGAAATGTAATTAAGTACCCATGACCAAAATCCCTAACGTGAGTTTTCGTTCACCTG  
2001 AGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGTAGATCCTTTTTCTGCGGTAATCTGCTGCTTGCAAAACAAAAAACACCGCTACCAGCG  
2101 GTGGTTTTTGGCCGATCAAGAGCTACCAACTCTTTTTCCGAAGTAACTGGCTTCAGCAGAGCGCAGATACCAATACTGTTCTTCTAGTGTAGCCGT  
2201 AGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCTACATACCTCGCTCTGTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTCTGTCT  
2301 TACCGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTGGGCTGAACGGGGGTTCTGTGCACACAGCCAGCTTGAGCGAACGACCTAC  
2401 ACCGAAGTGAATACCTACAGCGTGAGCTATGAGAAGCGCCAGCTTCCGAAGGAGAAAGCGGACAGGTATCCGGTAAGCGGCAGGGTGGAAACAG  
2501 GAGAGCGCACGAGGAGCTTCCAGGGGAAACGCCTGGTATCTTTATAGTCTGTGCGGTTTCGCCACCTCTGACTTGAGCGTGTATTTTGTGATGCTC  
PacI (2693)  
2601 GTCAGGGGGCGGAGCCTATGAAAAACGCCAGCAACGCGCCTTTTTACGTTCTGGCCTTTTGTGCGCTTTTGTGCTCATGTTCTTAATTAACCTG  
2701 CAGGGCTGAAATAACCTCTGAAAGAGGAACTTGGTTAGGTACCTTCTGAGGCTGAAAGAACGACTGTGGAATGTGTGTCAGTTAGGGTGTGAAAGTC  
2801 CCCAGGCTCCCGAGGAGGATGCAAAAGTATGCAAAAGTATGCAATTAAGTACGCAACCAAGTGTGAAAGTCCCAGGCTCCCGAGGAGGATGATG  
NotI (2972)  
2901 CAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCACTAGTTCGCCAGAGCGCGGAGGGCTCCAGCGCCGCCCTCCCGACAGCAGGGGCGG  
3001 GGTCCCGCCACCGAAGGAGCGGCTCGGGCGGGCGGCTGATTGCGCGGGCGGGCTGACGCCGACGCGGTATAAGAGACCACAAGCAGCCC  
3101 GCAGGGCCAGACTTCTTCCGCGAAGCTTCCGCTCAGAACGCAAGtgtaggggaggggtgagcttcgaggggcggcagctggaggtcctgctccgagcg  
3201 ggccggggccccgctgctgctggcgggatttagctgcagcattcccgttcgagttgcggcgccgggagggagagtgtagggcctagggcaacccc  
3301 gtacccctcgctcgtgctcggcctgagggcctagctggtgctccgcccggcggcggctgctactcggccgactcctggtctttttttttttgtgtgt  
3401 ttgcccgtgctcctcattgcttgcagcaataggggtaacaagggaggggtgagggcctgctcggcgagccggagaggtcatggttggggaggg  
3501 aatggagggacaggagtgccggtggggccgccccttcggagcacatgtccgacccactggatggggcagggcctggggttttcccgaagcaac  
3601 caggctggggttagcgtgcccagggcctggtggcccagcaccggcagcactggttggcggcggcggcttgcctgcctcctaactagggtagggc

